Issues that Matter Notification and Escalation

Slides:



Advertisements
Similar presentations
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Advertisements

The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
What Is Quality by Design?. Quality by Design: QbD Defined Prospectively examining the objectives of a trial and defining factors critical to meeting.
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
Standard 5: Patient Identification and Procedure Matching Nicola Dunbar, Accrediting Agencies Surveyor Workshop, 10 July 2012.
Basics of OHSAS Occupational Health & Safety Management System
Building Quality Assurance into Clinical Trials. Objectives for Today: Define Quality in Research Describe How to Initiate Corrective and Preventative.
Module J Audits and Inspections Patricia E. Koziol 1Module J Final Version 1-May-2010.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
INTRODUCTION TO LAND-USE ISSUES. Land-use planning Seveso II provisions (Art. 12) in case of: New establishments Modifications to existing ones Developments.
Hazards Identification and Risk Assessment
Conducting Clinical Risk Assessments And Implementing Compliance Practices Jane L. Stratton Chiron Corporation VP/Associate General Counsel Chief Compliance.
ISO Most Common Problems May 25, 2000 Underwriters Laboratories Inc. May 25, 2000 Underwriters Laboratories Inc.
OHSAS Occupational health and safety management system.
Business Continuity Planning 101
Responsibilities of Sponsor, Investigator and Monitor
Chapter 6 Internal Control in a Financial Statement Audit McGraw-Hill/IrwinCopyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved.

Good Clinical Practice (GCP) and Monitoring Practices
Risk Assessment Beginning an Analysis Date by Jim Bowman.
ASK MBSAQIP Agenda ASK MBSAQIP November 10, 2016 Time (CST)
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Incident Reporting And Investigation Program
An Overview on Risk Management
Audit of predetermined objectives
Responsibilities of Sponsor, Investigator and Monitor
EIA approval process, Management plan and Monitoring
Implementing a Successful Corrective and Preventative Action Program
QSY-Understanding Corrective and Preventive Action
SACSCOC Fifth-Year Readiness Audit
Legislative Compliance Management Insurance Industry Workshop 1 – 2 November 2005 Bangkok, Thailand Kim Norris Managing Director International Advisory.
Data Architecture World Class Operations - Impact Workshop.
12.3 Control Procurements The process of managing procurement relationships, monitoring contract performance and making changes or corrections as needed.
IRB reporting updates.
Dr. Patrick Rüdelsheim General Partner, Perseus BVBA
Reportable Events & Other IRB Updates February 2017
MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS
Good Clinical Practice
Fundamentals of ISO.
Corporate Governance Corporate Governance also plays an important role in maintaining corporate integrity and managing the risk of corporate fraud, combating.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
MAC Board Effectiveness Survey
Quarry Operator and Contractor Code of Conduct
ITPD ISSUE MANAGEMENT PROCESS SEPTEMBER 5, 2008
CMMI – Staged Representation
NHLBI Perspective Yves Rosenberg, M.D, M.P.H.
HIGHLIGHTING THE KEY CHANGES
Internal control - the IA perspective
Incident Reporting And Investigation Program
Lockheed Martin Canada’s SMB Mentoring Program
MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS
Operationalizing Export Certification and Regionalization Programmes
Masoud Solaymani-Dodaran Iran University of Medical Sciences
Taking the STANDARDS Seriously
MAC Board Effectiveness Survey
Project Management Group
Briefing to the Portfolio Committee on Police Audit outcomes of the Police portfolio for the financial year 13 October 2015.
Internal Control Internal control is the process designed and affected by owners, management, and other personnel. It is implemented to address business.
ISSUE MANAGEMENT PROCESS MONTH DAY, YEAR
Quality Assurance in Clinical Trials
Protocol Approval Criteria
Good clinical practice
Supplier Corrective ACTION RESPONSE REVIEW TRAINING
Handling of protocol deviations (PDs)
Presentation transcript:

Issues that Matter Notification and Escalation Approved for use 29 Jun 2016

Notification and Escalation Clinical Development Enterprise ISSUES Occurrences/Situations that require a simple correction, with no effect on clinical development activities, are managed through normal business processes and not via the issue management framework. Issues that Matter may need to be escalated in that they require immediate decision and action by and/or notification of relevant stakeholders.

Basic Principles To ensure rapid escalation and notification takes place, the organization should: Prospectively define Issues that Matter (leveraging the organization’s risk management processes), and Ensure that an appropriately designed escalation pathway is in place. Direct from manuscript

Basic Principles The nature, extent, and impact of the issue should drive the level to which escalation and/or notification occurs. A clearly defined communication pathway and triggers should focus attention on issues that could undermine the goals of the organization. Companies must consider defining and implementing appropriate documentation expectations to support the process. Direct from manuscript

Considerations An Issue that Matters requires notification and escalation to the appropriate levels of management. An Issue that Matters should be addressed with a sense of urgency based on its criticality. Activities in this process may happen concurrently depending on the type of Issues that Matters and company escalation procedures. A designated individual should take ownership of the issue that matters to ensure all aspects of notification and escalation activities are completed. The escalation process is not meant to replace CAPA process activities. This information may feed directly into the CAPA process. CAPA note?

Overview A decision tree model is a key tool that can enable proper notification and escalation pathways. Example Diagram: ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions

Notification ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions The Initial notification of an Issue that Matters should be in a timely manner to ensure immediate communication and awareness. Notifications should be made to all persons that need awareness of the Issue that Matters. For example, a RACI tool would provide a communication guideline. If additional notification is required after the initial communication, recipients should be identified based on the nature, extent, and impact of the issue. Notification should include the description and current status of the Issue that Matters. Notifications should continue to ensure impacted parties are aware of the ongoing status. These should include a summary of activities, tentative timeline, and point of contact for questions.

Escalation ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions An Issue that Matters should be escalated to appropriate management. This will ensure that the appropriate resources are assigned to address the issue in a timely manner. When escalating, include the description of the Issue that Matters, its current status, and any known activities that require direct and/or Senior Management input. After the initial escalation, if it is determined that additional escalation is required, recipients should be identified based on the nature, extent, and impact of the issue.

Escalation Decisions ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions Responses to an escalated Issue that Matters should be expected within an appropriate timeframe based on the severity of the problem. The person escalating the issue should communicate this expectation to the escalation recipient(s). Consider the nature, extent, impact and prevention of any unintended consequences when making decisions and taking immediate actions. Track all escalation decisions and immediate actions to completion and communicate status as appropriate. Examples of decisions include: How to contain Decision to immediately stop enrolling patients Conduct a “for cause” audit Escalate to higher level of management based on the severity Consider: Some of these decisions and actions may be an input into the CAPA process for documenting the immediate response.

Complete the Process ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions The Issue Owner should document the escalation activities and outcomes. The Issue Owner should communicate next steps to management and notification recipients.

Notification & Escalation Process Examples ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions These are hypothetical , generalized examples. The actions identified in these examples should not replace any company-specific procedures. Specific actions and order of actions may differ by company.

Scenario #1 Issue: Background Information: ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions Issue: Study XYZ had a site where 7 subjects violated Critical Inclusion Criterion A at 1 site. The study monitor discovered this during the first visit after the enrollment began, per the monitoring plan. Background Information: If more than 25 subjects violate 1 of 3 critical inclusion criteria for Study XYZ, their required exclusion from the per protocol analysis will result in a loss of statistical power. Company ABC has set their Threshold for Action at 5 subjects violating at least 1 of the 3 criteria. This is now an “Issues that Matter” based on this established threshold.

Scenario #1 ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions Per Company ABC’s procedure for Issue Escalation, the Study Monitor notifies the Monitoring Manager. The Monitoring Manager escalates to the Study Program Manager.

Scenario #1 ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions The Study Program Manager takes ownership of the Issue that Matters. Based on Company ABC’s Issue Escalation SOP, the Study Program Manager escalates the Issue that Matters and calls an immediate meeting of all of the Escalation Recipients including: Direct management Clinical compliance management Study designated physician Safety management

Scenario #1 ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions The following decisions are made during the escalation meeting: Suspend enrollment at the site. Safety will determine the potential impact to the subjects. Compliance is assigned to investigate the cause of the non-compliance at the site and confirm that it is not a systemic issue. Study Designated Physician will determine if continued participation of the affected subjects in the study is in the subjects’ best interest. Statistics will determine the impact to the study data from the site. Clinical QA will determine if there is misconduct and if a directed audit is warranted. Note: Some of these decisions will be inputs of the CAPA process.

Scenario #1 ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions The escalation meeting also identifies additional areas that should be subject to notification: Statistics, Data Management, and Regulatory representatives receive notification of the Issue that Matters by email. Note: This notification is for awareness only, they do not have immediate actions and/or decisions to weigh in on at this time.

Scenario #1 ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions The Study Program Manager documents all decisions and escalation activities. The Study Program Manager communicates CAPA status at regular time points and any additional escalation activities or containment actions to management and notification recipients.

Scenario #2 Issue: Background Information: ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions Issue: Study Monitor suspects fraud at an Investigator’s site. Background Information: Fraud was suspected at the ACME Investigator site for Study XYZ by the study monitor. The Study Monitor suspected that study records had been falsified. The falsification of study records impacts safety, quality, and regulatory aspects of the study. This is identified as an Issue that Matters and will require notification and escalation.

Scenario #2 ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions Study Monitor notifies their direct management of the Issue that Matters. The Monitoring Manager is the direct manager of the Study Monitor. Per company SOP, the Monitoring Manager then escalates the Issue that Matters to Clinical Compliance management. Clinical Compliance management then takes ownership of the Issue that Matters.

Scenario #2 Additionally, the Issue that Matters is escalated to: Notification Identify Recipients Close Escalation Decisions Additionally, the Issue that Matters is escalated to: GCP QA Program Manager GCP QA Director Clinical Program Lead Monitoring Management Lead

Scenario #2 ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions The following decisions were made during the escalation meeting including the previously identified escalation recipients: Senior Management will decide if the data from the site needs to be removed from the data set and if the site needs to be closed. QA will conduct an audit to confirm suspected fraudulent activities. A CAPA will be initiated to investigate the cause and breadth of the fraud and determine appropriate corrective actions. Regulatory will decide if the FDA needs to be notified. Statistics will determine the impact to the study data.

Scenario #2 ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions Regulatory, Safety, Statistics and Data Management representatives will be notified of the Issue that Matters. Additionally, Regulatory and Statistics will be notified of their assigned activities identified during the escalation meeting.

Scenario #2 ISSUE THAT MATTERS Notification Identify Recipients Close Escalation Decisions Clinical Compliance management should document all decisions and escalation activities. Appropriate documentation should be included in the CAPA process activities. Clinical Compliance management communicates CAPA status at regular time points and any additional escalation activities or containment actions to management and notification recipients.